$2.76 Billion is the total value of PFM Health Sciences, LP's 85 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | OAK STR HEALTH INCnote 3/1 | $48,857,000 | – | 63,000,000 | +100.0% | 1.77% | – | |
| XLK | New | SELECT SECTOR SPDR TRput | $45,552,000 | – | 383,500 | +100.0% | 1.65% | – |
| BIIB | New | BIOGEN INCcall | $44,536,000 | – | 166,800 | +100.0% | 1.61% | – |
| PEN | New | PENUMBRA INCcall | $39,342,000 | – | 207,500 | +100.0% | 1.42% | – |
| BIIB | New | BIOGEN INC | $37,200,000 | – | 139,326 | +100.0% | 1.35% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $34,903,000 | – | 4,515,216 | +100.0% | 1.26% | – |
| HCA | New | HCA HEALTHCARE INC | $32,206,000 | – | 175,235 | +100.0% | 1.16% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INCcall | $15,259,000 | – | 180,000 | +100.0% | 0.55% | – |
| OM | New | OUTSET MED INC | $11,620,000 | – | 729,413 | +100.0% | 0.42% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $8,590,000 | – | 130,366 | +100.0% | 0.31% | – |
| New | NEVRO CORPnote 2.750% 4/0 | $8,519,000 | – | 9,000,000 | +100.0% | 0.31% | – | |
| APLS | New | APELLIS PHARMACEUTICALS INC | $8,324,000 | – | 121,880 | +100.0% | 0.30% | – |
| CANO | New | CANO HEALTH INC | $6,736,000 | – | 776,893 | +100.0% | 0.24% | – |
| PRTA | New | PROTHENA CORP PLCcall | $4,881,000 | – | 80,500 | +100.0% | 0.18% | – |
| LUNG | New | PULMONX CORP | $3,327,000 | – | 199,703 | +100.0% | 0.12% | – |
| CELC | New | CELCUITY INC | $1,410,000 | – | 140,426 | +100.0% | 0.05% | – |
| ZLAB | New | ZAI LAB LTDadr | $808,000 | – | 23,612 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.